Protara Therapeutics, Inc. (TARA) News
Filter TARA News Items
TARA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest TARA News From Around the Web
Below are the latest news stories about PROTARA THERAPEUTICS INC that investors may wish to consider to help them evaluate TARA as an investment opportunity.
Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic OncologyNew results from six patients with HGTa papillary tumors show five of six patients with HGRFS at Week 12Data continue to support favorable tolerability of TARA-002 in patients with NMIBCAs previously reported, anti-tumor activity observed in all three evaluable patients with CIS, including one heavily pre-treated BCG-unresponsive patient who achieved a complete responseCompany remains on track to report preliminary results from the expansion portion of the ADVANCED-1 trial in NMIBC patients with |
Protara Therapeutics Inc (TARA) Announces Q3 2023 Financial ResultsCompany reports increased R&D expenses and a net loss, but remains optimistic about future milestones |
Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business UpdateDosing is progressing well in ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS; preliminary results expected in 1H24Company initiated ADVANCED-2 trial evaluating TARA-002 in NMIBC patients with BCG-unresponsive CIS and BCG-naïve CIS Company initiated Phase 2 trial of TARA-002 in Lymphatic Malformations Cash, cash equivalents and investments of $74M as of September 30, 2023 expected to fund operations into Q2 of 2025 NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Protara Therapeuti |
Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic MalformationsNEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that dosing is now underway in the Phase 2 STARBORN-1 trial evaluating TARA-002, an investigational cell-based immunopotentiator, for the treatment of pediatric patients with lymphatic malformations (LMs). “There is a pressing need for an effective FDA-approved therapy to treat LMs, a rar |
Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in SituDosing is progressing on schedule in ongoing ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS; preliminary results expected in 1H24NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that dosing is now underway in its Phase 1b/2 ADVANCED-2 trial evaluating intravesical instillation of TARA-002, the Company’s investigatio |
Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and... |
Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, at 9:30 am ET in New York. The live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: https://i |
Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business UpdateDosing is progressing on schedule in ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS; preliminary results expected in 1H24Company plans to commence dosing in ADVANCED-2 trial evaluating TARA-002 in NMIBC patients with BCG-unresponsive CIS and BCG-naïve CIS in 4Q23Company plans to initiate Phase 2 trial of TARA-002 in Lymphatic Malformations in 4Q23Cash, cash equivalents and investments of $80M as of June 30, 2023 expected to fund operations into 2025 NEW YORK, Aug. 03, 2023 (G |
Protara Therapeutics Announces Dosing of First Patients in Phase 1b ADVANCED-1EXP Trial of TARA-002 in NMIBC Patients with Carcinoma in SituDosing of first patients follows recent presentation of positive preliminary data from Phase 1a dose escalation portion of ADVANCED-1 trialCompany advancing NMIBC clinical development program, with Phase 1b/2 trial in BCG-unresponsive CIS patients and in BCG-naïve and BCG-exposed CIS patients expected to initiate in 2H’2023 NEW YORK, May 15, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer |
Protara Therapeutics Announces First Quarter 2023 Financial Results and Business UpdateFavorable tolerability and anti-tumor activity observed in NMIBC patients treated with TARA-002 in ADVANCED-1 trialCompany plans to initiate ADVANCED-2 trial in BCG-naïve CIS patients and BCG-unresponsive CIS patients in 2H23 Regulatory clearance received from FDA to commence Phase 2 trial of TARA-002 in Lymphatic Malformations; trial expected to initiate in Q423Continue to expect cash, cash equivalents and investments of $90M as of March 31, 2023 to fund operations into 2025 NEW YORK, May 04, 2 |